<DOC>
	<DOCNO>NCT01772940</DOCNO>
	<brief_summary>In resource-limited setting , concern remain regard emergence virologic failure high-level drug resistance mutation ( DRM ) WHO recommend first-line antiretroviral therapy ( ART ) non-nucleoside reverse transcriptase inhibitor ( NNRTI ) base regimen Human immunodeficiency virus 1 ( HIV1 ) infect patient . The study hypothesis boosted-protease inhibitor regimen well outcome NNRTI-based regimen low genetic barrier resistance . The study randomize , multicenter , factorial trial ( conduct Congo ) , treatment- naïve adult receive 96 week ritonavir- boost lopinavir ( LPV/r ) nevirapine ( NVP ) combination tenofovir ( TDF ) /emtricitabine ( FTC ) zidovudine ( ZDV ) /lamivudine ( 3TC ) . The primary end point incidence therapeutic ( clinical and/or virologic ) failure study week 24 .</brief_summary>
	<brief_title>Nevirapine vs Ritonavir-boosted Lopinavir ART Naive HIV-infected Adults Resource Limited Setting</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Antiretroviraltherapy naïve HIV1 infect Adults WHO clinical stage 3 CD4 &lt; 350/mm3 WHO clinical stage 4 CD4 cell count &lt; 200/mm3 Negative pregnancy test Hemoglobin &lt; 8.5 g/dL ( female ) 9.0 g/dL ( male ) Estimated Glomerular Filtration Rate &lt; 50 ml/ minute ( CockcroftGault equation ) Hepatic transaminase ( AST ALT ) &gt; 3 x upper limit normal Active tuberculosis Pregnancy Females breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>First-line therapy</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Non-Nucleoside Reverse transcriptase Inhibitor</keyword>
	<keyword>Resource-limited setting</keyword>
</DOC>